The device was not included as a potential treatment despite sham-controlled evidence showing it reduces patient symptoms.

With the pandemic having worsened burnout and intent to leave, the authors say keeping and supporting the workforce is ...

Sugar substitutes, substance abuse, GLP-1 drugs, and the biggest clinical trials of the year—each had their place in our top ...

Newer therapies for multiple conditions were major stories this year, but long-term HF survival gains seem to have vanished.

More than ever, early-career physicians are looking for ways to fill gaps left by traditional education while maximizing ...

Check out all our end-of-year content—the latest Heart Sounds podcast reviews the reporters’ own favorite stories for 2024, ...

The year had a lot to offer, from advanced therapies aimed at Lp(a), GLP-1, and other targets, to support for simpler ...

Both EACTS and STS have taken measures against bullying, disrespect, and other harmful behavior. Others may follow suit.

It was a big news year for structural heart disease. For tricuspid regurgitation, two devices were approved in quick succession by the US Food and Drug Administration, then later in 2024, long-awaited ...